Gilead Sciences, Inc. (GILD)
| Previous close | 65.54 |
| Open | 65.43 |
| Bid | 65.86 x 200 |
| Ask | 65.94 x 300 |
| Day's range | 65.16 - 66.14 |
| 52-week range | 64.33 - 87.87 |
| Volume | |
| Avg. volume | 7,315,981 |
| Market cap | 82.163B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 183.03 |
| EPS (TTM) | 0.36 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.08 (4.70%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | 81.81 |
Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.
Insider Monkey23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months. If you want to skip our detailed analysis of these stocks, go directly to 5 Most Profitable Stocks of the Last 12 Months. The United States stock market has come a long way since the turn of the millennium more […]
ZacksThe Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
